SALİH KARATLI, İSMAİL DİLLİ, MUSTAFA ALTINBAŞ
Anatolian Current Medical Journal - 2025;7(4):513-517
Aims: The CALLY index, integrating C-reactive protein (CRP), albumin, and lymphocyte count, has been identified as a promising prognostic biomarker in various cancers. The present study aims to evaluate its prognostic significance in De Novo metastatic colorectal cancer (mCRC). Methods: A retrospective analysis was conducted on 108 patients diagnosed with de novo mCRC at Ankara Etlik City Hospital (2021–2024). The CALLY index was calculated from baseline laboratory values and dichotomized at the median (0.2018). Progression-free survival (PFS) and overall survival (OS) were compared between low and high CALLY groups using the Kaplan–Meier method and log-rank test. The associations between the CALLY index and tumour location, as well as RAS/BRAF mutation status, were evaluated using the chi-square test. Cox regression analyses were also performed to determine independent prognostic factors. Results: Patients with elevated CALLY scores exhibited significantly prolonged median PFS (24.0 vs. 13.0 months; p<0.001) and OS (not reached vs. 15.0 months; p<0.001) in comparison to those with low scores. Low CALLY scores were found to be associated with RAS mutations (p=0.03) and tumour location (p=0.04), but not BRAF mutations (p=0.37). In multivariate Cox regression analysis, a high CALLY score remained an independent prognostic factor for both PFS and OS. Conclusion: A low CALLY index is associated with shorter durations of PFS and OS in patients harboring RAS mutations and right-sided tumour location. Its simplicity and practicality suggest considerable promise for routine clinical use, pending confirmation in large prospective studies.
